Ingrezza is the first FDA-approved treatment for tardive dyskinesia, or uncontrolled movements of the face and body. The irreversible movement disorder occurs in 5 to 8 percent of patients taking antipsychotic drugs.
Neurocrine said the drug would be priced competitively. Last year, Neurocrine estimated Ingrezza’s net price at $20,000 to $60,000 annually, depending on dosages, reports Reuters.
The drug company plans to launch Ingrezza — its first commercial product — in May.
More articles on supply chain:
FDA identifies safety issues at Mylan HIV drug facility in India
Supply chain tip of the week: Hospital linens cost more than you think
Survey: 5% of healthcare leaders think Trump will take ‘meaningful’ action on drug prices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.